Lutetium (177Lu) vipivotide tetraxetan

(Pluvicto®)

Lutetium (177Lu) vipivotide tetraxetan

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 1000 MBq/mL (27 mCi/mL))
Drug ClassRadioligand therapeutic agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Pluvicto (lutetium (177Lu) vipivotide tetraxetan) Prescribing Information.2022Advanced Accelerator Applications USA, Inc., Millburn, NJ

Systematic Reviews / Meta-Analyses